GlassScriptPhysician profile
Tiffany E Madison
NPI 1841497054
$4,996.32
in general payments reported to CMS, 2019-2025
45 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $1,323 · 2021: $956 · 2022: $540 · 2023: $161 · 2024: $171 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $767.05 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $584.44 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $524.95 | 2019-2025 | Lokelma, Farxiga |
| Takeda Pharmaceuticals U.S.A., INC. | $276.46 | 2019-2022 | |
| Abbvie INC. | $271.76 | 2019-2025 | |
| Lilly USA, LLC | $219.04 | 2019-2025 | Mounjaro |
| Allergan, INC. | $215.18 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $210.75 | 2019-2021 | |
| Amarin Pharma, INC. | $158.29 | 2020-2022 | |
| Astellas Pharma US INC | $156.49 | 2019-2024 | Veozah |
| Horizon Therapeutics Plc | $141.32 | 2019-2021 | |
| Pfizer INC. | $141.16 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.79 | 2020-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $93.80 | 2019-2021 | |
| Antares Pharma, INC. | $69.88 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Madison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.